Jonathan Wygant - Veracyte VP Officer
| VCYT Stock | USD 44.12 1.17 2.72% |
Insider
Jonathan Wygant is VP Officer of Veracyte
| Age | 53 |
| Address | 6000 Shoreline Court, South San Francisco, CA, United States, 94080 |
| Phone | 650 243 6300 |
| Web | https://www.veracyte.com |
Latest Insider Transactions
Jonathan Wygant Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Wygant against Veracyte stock is an integral part of due diligence when investing in Veracyte. Jonathan Wygant insider activity provides valuable insight into whether Veracyte is net buyers or sellers over its current business cycle. Note, Veracyte insiders must abide by specific rules, including filing SEC forms every time they buy or sell Veracyte'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Wygant few days ago Disposition of 5032 shares by Jonathan Wygant of Veracyte at 42.8922 subject to Rule 16b-3 | ||
Jonathan Wygant over six months ago Acquisition by Jonathan Wygant of 23942 shares of Veracyte subject to Rule 16b-3 |
Veracyte Management Efficiency
The company has return on total asset (ROA) of 0.0107 % which means that it generated a profit of $0.0107 on every $100 spent on assets. This is way below average. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.09 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 1.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| ACA ACA | Solid Biosciences LLC | 56 | |
| Peter BSc | Syndax Pharmaceuticals | 55 | |
| Simon MBBS | Keros Therapeutics | 54 | |
| Jonathan MBA | Viridian Therapeutics | 49 | |
| Hennie Hoogenboom | Merus BV | N/A | |
| Alexander Bakker | Merus BV | 58 | |
| Kristian MBA | Viridian Therapeutics | 49 | |
| Sushil Patel | Replimune Group | 53 | |
| Joanna Siegall | Cytokinetics | N/A | |
| Nathalie MD | Enanta Pharmaceuticals | 58 | |
| Kevin Giordano | Rocket Pharmaceuticals | N/A | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| Keith MBA | Keros Therapeutics | 54 | |
| Stephen MD | Kura Oncology | 52 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Annie Ganot | Solid Biosciences LLC | N/A | |
| Anjali Ganguli | Syndax Pharmaceuticals | 47 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| Richard BA | MeiraGTx Holdings PLC | 51 | |
| Harry Shuman | Merus BV | N/A | |
| Vahe Bedian | Viridian Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.0083 | ||||
| Return On Asset | 0.0107 |
Veracyte Leadership Team
Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Brainin, Executive Officer | ||
| John Leite, Chief Business | ||
| Annie McGuire, Sr Counsel | ||
| Tracy Morris, VP Communications | ||
| Corinne Danan, Senior President | ||
| Tina Nova, Director | ||
| Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee | ||
| Keith Gligorich, Senior Operations | ||
| Rebecca Chambers, Executive CFO | ||
| Jonathan Wygant, VP Officer | ||
| Phillip MD, Chief Officer | ||
| Beverly CPA, VP Controller | ||
| Karen Possemato, Communications Marketing | ||
| Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer | ||
| Steven French, Senior Officer | ||
| Marc Stapley, CEO Director |
Veracyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0083 | ||||
| Return On Asset | 0.0107 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 3.07 B | ||||
| Shares Outstanding | 77.5 M | ||||
| Shares Owned By Insiders | 0.77 % | ||||
| Shares Owned By Institutions | 99.23 % | ||||
| Number Of Shares Shorted | 2.88 M | ||||
| Price To Earning | (10.61) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.